Investigator

Francesco Baschieri

Assistant professor · Innsbruck Medical University, Pathophysiology

FBFrancesco Baschie…
Papers(2)
Loading of Dicarboxyl…The Rab25‐ …
Collaborators(6)
Hristo P. VarbanovIrena Pashkunova‐Mart…Stefan SchwaigerAmelie ScherflerBrigitte KircherDaniel Baecker
Institutions(4)
Universitt InnsbruckMedical University of…Innsbruck Medical Uni…Freie Universität Ber…

Papers

Loading of Dicarboxylatoplatinum(II)‐NHC Complexes in Bacterial Ghosts as an Advanced Development in Cancer Therapy

ABSTRACT This study aimed to improve the drug‐like properties of benzimidazole‐based Pt(II)‐N‐heterocyclic carbene (NHC) complexes, particularly by enhancing their water solubility and delivery to cancer cells. Accordingly, four new Pt(II) complexes of the benzimidazol‐2‐ylidene type, featuring monodentate carboxylato ligands, were prepared and their structures confirmed through a combination of spectroscopic and crystallographic techniques. Their stability in aqueous solution and cell culture medium was investigated by 1 H NMR spectroscopy and HPLC‐MS analysis. Cytotoxicity was assessed using the MTT assay in ovarian cancer cell lines (A2780wt (cisplatin sensitive) and A2780cis (cisplatin resistant)) and a noncancerous bone marrow stromal cell line (HS‐5). Most complexes exhibited cytotoxicity comparable to or exceeding that of carboplatin, with preferential activity toward cancer cells. Loading of all four Pt(II) complexes into bacterial ghost cells (BGs) derived from two different nonpathogenic bacterial strains, Escherichia coli (E. coli) Nissle 1917 and E. coli NM522 notably enhanced the intracellular accumulation and cytotoxicity. Furthermore, mechanistic studies demonstrated that all tested compounds, regardless of formulation, induced apoptosis. Their potential to trigger immunogenic cell death was also evaluated, though only a modest effect was observed on selected hallmarks. Collectively, these findings highlight the potential of dicarboxylatoplatinum(II)‐NHC complexes, particularly loaded into BG‐based formulations, as promising anticancer drug candidates.

24Works
2Papers
6Collaborators
EndocytosisCell Line, TumorOvarian NeoplasmsApoptosisTumor MicroenvironmentCancer-Associated FibroblastsNeoplasm Metastasis

Positions

2023–

Assistant professor

Innsbruck Medical University · Pathophysiology

2021–

CRCN

INSERM · U1279

2015–

Post-doc

Gustave Roussy · Recherche

Education

2015

PhD/Dr.rer.nat.

Universität Konstanz Fachbereich Biologie

2013

Vanderbilt University · cell and developmental biology

2010

MSc - Physiopathological Sciences

Università degli Studi di Pisa · Scienze Matematiche, Fisiche e Naturali

2008

BSc Molecular Biology

Università degli Studi di Pisa · Scienze Matematiche, Fisiche e Naturali

Country

FR